CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 120 filers reported holding CYMABAY THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.59 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,689,119 | +39.4% | 381,564 | +2.4% | 1.10% | +45.2% |
| Q2 2023 | $4,080,233 | +47.8% | 372,624 | +17.7% | 0.76% | +39.5% |
| Q1 2023 | $2,760,700 | -20.0% | 316,594 | -42.5% | 0.54% | -24.1% |
| Q4 2022 | $3,451,447 | +190.3% | 550,470 | +62.0% | 0.71% | +176.7% |
| Q3 2022 | $1,189,000 | -53.6% | 339,778 | -4.1% | 0.26% | -57.6% |
| Q3 2020 | $2,565,000 | +98.7% | 354,337 | +268.4% | 0.61% | +198.0% |
| Q2 2018 | $1,291,000 | -70.2% | 96,188 | -71.2% | 0.20% | -71.7% |
| Q1 2018 | $4,335,000 | +8.6% | 333,737 | -23.1% | 0.72% | +1.0% |
| Q4 2017 | $3,991,000 | -16.6% | 433,813 | -27.0% | 0.72% | +12.4% |
| Q3 2017 | $4,788,000 | – | 594,004 | – | 0.64% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
| Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
| Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
| Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
| Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
| ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
| TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
| Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
| Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
| Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |